Want to see TSE:RVX full AI Analyst Report?
Resverlogix (RVX) AI Stock Analysis
Resverlogix
(TSX:RVX)
The overall score of 42 is critically low, driven primarily by the company's dire financial state. The balance sheet is insolvent with negative equity and a massive debt load, while the income and cash flow statements show a complete lack of revenue and persistent, deep losses. The only factor preventing a minimum score is a modestly positive technical trend, with the stock price trading above several key moving averages, suggesting some nascent market optimism. However, this technical strength is fragile and heavily outweighed by the fundamental risk of financial collapse.
Resverlogix (RVX) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 25.82M
- Dividend Yield
- ―
- Average Volume (3M)
- 26.87K
- Price to Earnings (P/E)
- -1.5
- Beta (1Y)
- 0.70
- Revenue Growth
- ―
- EPS Growth
- 15.04%
- Country
- Canada
- Employees
- 17
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Resverlogix Business Overview & Revenue Model
Company Description
Resverlogix Corporation is a biotechnology firm currently in advanced clinical development, concentrating on developing treatments for illnesses where existing medical solutions are inadequate. The company's leading therapeutic compound is apabetalon...
Resverlogix Financial Statement Overview
Summary
The company is in a state of severe financial distress. It generates zero revenue, has deeply negative net income and cash flows, and a balance sheet with negative stockholders' equity of -$94.1M against a $77.6M debt load, indicating technical insolvency. The only minor positive is a narrowing of operating losses, but this is insufficient to raise the score from the minimum.
Income Statement
1Very NegativeBalance Sheet
1Very NegativeCash Flow
1Very Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -421.65K | -437.53K | -476.75K | ― | 0 | 0 |
| EBITDA | -3.60M | -4.77M | -4.25M | -4.46M | -11.74M | -14.87M |
| Net Income | -10.84M | -7.90M | -7.63M | -16.74M | -3.61M | -24.77M |
Balance Sheet | ||||||
| Total Assets | 8.24M | 7.93M | 7.34M | 6.57M | 8.12M | 9.98M |
| Cash, Cash Equivalents and Short-Term Investments | 79.87K | 107.80K | 99.00K | 5,000 | 40.00K | 6,000 |
| Total Debt | 77.62M | 72.77M | 81.97M | 9.91M | 6.49M | 7.04M |
| Total Liabilities | 102.36M | 96.73M | 89.08M | 81.04M | 67.40M | 69.85M |
| Stockholders Equity | -94.12M | -88.80M | -81.73M | -74.47M | -59.28M | -59.87M |
Cash Flow | ||||||
| Free Cash Flow | -4.06M | -3.73M | -4.36M | -2.96M | -3.99M | -8.90M |
| Operating Cash Flow | -3.76M | -3.73M | -3.89M | -2.51M | -3.54M | -8.02M |
| Investing Cash Flow | -684.75K | -660.36K | -377.00K | -516.00K | -473.00K | -833.00K |
| Financing Cash Flow | 4.83M | 4.39M | 4.36M | 2.99M | 4.06M | 8.81M |
Resverlogix Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:RVX, the sentiment is Negative. The current price of 0.07 is below the 20-day moving average (MA) of 0.08, below the 50-day MA of 0.09, and below the 200-day MA of 0.10, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 31.80 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:RVX.
Resverlogix Peers Comparison
Overall Rating
TSE:MBX52Neutral- TSE:RVX42Neutral
TSE:BCT39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TSE:MBX | 52Neutral | CAD 41.09M | -8.64 | -18.83% | ― | -27.13% | -1752.63% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| TSE:RVX | 42Neutral | CAD 25.82M | -1.55 | 10.92% | ― | ― | 15.04% |
| TSE:BCT | 39Underperform | CAD 37.55M | -0.33 | -170.70% | ― | ― | 87.90% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:RVX | Resverlogix Corp. | 0.07 | -0.03 | -25.00% | |
| TSE:BCT | BriaCell Therapeutics | 4.29 | -9.85 | -69.66% | |
| TSE:MBX | Microbix Biosystms | 0.29 | 0.03 | 13.73% | |
| TSE:GSD | Devonian Health Group, Inc. | 7.74 | -2.16 | -21.82% | |
| TSE:TTI | Thiogenesis Therapeutics Corp | 0.63 | -0.12 | -16.00% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 26, 2026